Adrenomed AG is a privately held, clinical stage biopharmaceutical company focused on the development of pioneering therapies to rescue vascular integrity and save the lives of critically ill patients. Founded in 2009 by a management team with decades of experience in sepsis and a deep knowledge of diagnostics and drug development, Adrenomed translates the concept of personalized medicine into acute care. Lead product candidate is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity.
A biomarker-guided Phase II clinical trial (AdrenOSS-2, NCT03085758) in 301 patients with early septic shock was successfully completed. The antibody, given on top of standard of care, showed a favourable safety profile and demonstrated a positive trend on survival.
Adrenomed at a glance:
|Field of Activity
||The company’s goal is to rescue vascular integrity, an underlying pathophysiology in life-threatening conditions associated with
increased vascular leakage, congestion and shock. The developed technology targets Adrenomedullin, a peptide hormone with protective effects on endothelial barrier integrity. Current lead indication is septic shock.
|Technology||Adrenomed’s lead product candidate is a first-in-class antibody targeting the peptide hormone Adrenomedullin. The humanized antibody binds to Adrenomedullin in the blood, thereby trapping and stabilizing the peptide. This results in increased Adrenomedullin concentrations within the circulation. Antibody-bound Adrenomedullin is still functional, allowing the hormone to positively affect the integrity of the endothelial barrier. In clinical development, a unique approach is applied that combines targeted therapy with diagnostics using biomarkers to define the patient population. A strong IP position and patents granted in all major markets
effectively secure Adrenomed’s business.
|Unique Selling Point||Adrenomed develops a pioneering targeted therapy to address loss of vascular integrity, an unmet life-threatening pathophysiology, in septic shock.|
|Membership in network/associations||Biotechnology Innovation Organization, BPI, BIO Deutschland|
|Date of Incorporation/
Number of Employees
|Telephone/Telefax||+49 3302 2078-0/-15|
|Social media||LinkedIn Twitter|